AcquisitionOther

VERACYTE, INC. acquired Convergent Genomics, Expanding its Urology Diagnostics Portfolio

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

VERACYTE, INC. -> Convergent Genomics, Expanding its Urology Diagnostics Portfolio · $150 million

The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfolio.

Open source record (SEC) ↗